DANIEL BEGEL: Open Payments
NPI 1376609149 · SANTA MONICA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$809 in 26 payments from 8 companies in 2025. Trend: 2023 $698 · 2024 $512 · 2025 $809
Food & beverage: $809
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $208 |
| Alkermes, Inc. | 7 | $200 |
| Neurocrine BioSciences, Inc. | 5 | $156 |
| E.R. Squibb & Sons, L.L.C. | 2 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Lundbeck LLC | 2 | $45 |
| ABBVIE INC. | 2 | $34 |
Products named: REXULTI, ARISTADA, INGREZZA, CAPLYTA, UZEDY, VIVITROL, VRAYLAR, COBENFY.
Industry payments across CA — which companies pay providers there.
